Embodiments herein include an attenuated live vaccine composition for protection against Neisseria spp. infection, the vaccine composition comprising an effective amount of Snodgras sella alvi (S. alvi), or an antigen component thereof, and methods for treating or preventing disease related to or aggravated by Neisseria gonorrhoea is provided.

The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Glaucoma or pathogenic intraocular pressure is treated by locally administering to an eye in need thereof formulations of a Wnt5a receptor inhibitor.

Glaucoma or pathogenic intraocular pressure is treated by locally administering to an eye in need thereof formulations of a Wnt5a receptor inhibitor.

According to some embodiments, a topical composition and method of forming the same are provided, comprising a powder complex including an active component, wherein the powder complex has a pre-defined first dosage; and a universal activator serum having a pre-defined second dosage, wherein the combination of the powder complex and the universal activator serum generates the topical composition having a third pre-defined dosage and a viscosity of 10-30K centipoise (CPS). Numerous other aspects are provided.

According to some embodiments, a topical composition and method of forming the same are provided, comprising a powder complex including an active component, wherein the powder complex has a pre-defined first dosage; and a universal activator serum having a pre-defined second dosage, wherein the combination of the powder complex and the universal activator serum generates the topical composition having a third pre-defined dosage and a viscosity of 10-30K centipoise (CPS). Numerous other aspects are provided.

A composition includes at least one of a modified glucal or galactal molecule. The molecules are useful for the treatment of cancer, particularly in a human patient, more particularly in a human patient exhibiting cell-specific increases in glucose uptake without a corresponding lactate production. The compounds are also useful for treating a human that has hypoxic cells expressing elevated levels of HIT activity, a plurality of cells displaying a lower amplitude of circadian oscillation or an increase in reactive oxygen species in mitochondria of the cells of the human.

The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamated alpha tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).